Drs Olga Brieieva and Martin Higgs discuss in vitro genomic models for predicting clinical resistance to PARP inhibitors for ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc. (NASDAQ:IMNN) has a number of important events planned for June 2025 that we ...

HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations is usually treated with an anthracycline and a taxane ... If the breast cancer is also HR positive, ...

SAN ANTONIO — Risk-reducing surgery appeared linked with improved outcomes among BRCA mutation carriers diagnosed with early breast cancer, according to study results presented at San Antonio ...

BRCA2 gene mutations are hereditary changes that can raise cancer risk. Learn about the the types of cancer and options for screening and treatment. Skip to content. ... Aslanian HR, Lee JH, Canto MI.

Mrs. O M, a 38-year-old HR head in a Bank, developed pain in the abdomen and bloating 3 years ago. ... The BRCA 2 gene mutation is also responsible for some male breast cancers.

The following is a summary of "Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial," published in ...

In addition to BRCA2, BRCA1 is a well-known player in the HR pathway (Chen et al, 2018). To test whether the FEN1/EXO1 inhibition affects BRCA1-deficient cells to a similar extent, we established PARG ...

Investigators reported a significantly longer PFS in the experimental arm vs the control arm of 24.8 vs 16.6 months (HR, 0.66; 95% CI, 0.54-0.81; P =.001). 3 Further research with PARP inhibitors such ...

BRCA2 mutations in metastatic castration-resistant prostate cancer (mCRPC) confer sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. However, additional factors predicting PARP inhibitor ...

It also showed that HR- luminal BRCA2-mutant cells became more susceptible to tumour formation only after multiple stresses, suggesting that distinct mechanisms drive the transformation of HR- and ...

Breast cancers in individuals carrying germline BRCA1 and BRCA2 mutations often test HR positive. 2 These breast cancers, particularly those in BRCA1/2 carriers, typically exhibit a more ...